eFFECTOR Therapeutics, Inc.

LifeSci Acquisition 2 Corp, trading under the ticker LWAC and sponsored by LifeSci Capital, filed an S-1/A registration statement amendment on October 1, 2021, in connection with its proposed business combination with eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology. The SPAC completed its IPO in early 2021, targeting the healthcare and life sciences sector. eFFECTOR Therapeutics develops small-molecule drugs that regulate the eIF4F translation initiation complex, with lead programs aimed at treating cancer. The S-1/A, filed under accession number 0001193125-21-289863, represents an amendment to the de-SPAC registration statement with the SEC. Sign up at SpacDesk for full filing history, timeline data, and deal analytics on LWAC and hundreds of other SPACs.